PD-L1 Biomarker Testing Market

Global PD-L1 Biomarker Testing Market Forecast

The global PD-L1 biomarker testing market is expected to be valued at US$ 840.10 Million in 2026 and is projected to reach US$ 1,468.01 Million by 2033, growing at a CAGR of 8.3% between 2026 and 2033. The National Comprehensive Cancer Network (NCCN) continuously updates its clinical practice guidelines to include PD-L1 testing as a prerequisite for first-line immunotherapy selection, sustaining institutional procurement demand across academic medical centres and community oncology networks.

With Bristol-Myers Squibb's Opdivo and Merck and Co., Inc.'s Keytruda each generating combined global revenues exceeding US$ 30 Billion annually, the volume of patients requiring companion diagnostic testing provides a durable, revenue-linked demand floor that makes an 8.3% CAGR highly credible through 2033.

Key Highlights 

• North America leads the PD-L1 biomarker testing market with US$ 346.96 Million in 2026, supported by strong companion diagnostic regulations, reimbursement coverage, and extensive oncology testing infrastructure.
• Haematological Malignancies are the fastest-growing test type, driven by expanding approvals of PD-1/PD-L1 therapies and increasing companion diagnostic requirements in blood cancers.
• Immunohistochemistry (IHC)-Based Testing dominates with a 71.8% market share, owing to its established regulatory validation, widespread laboratory adoption, and high switching costs.
• Blood-Based Liquid Biopsy is the fastest-growing sample type, supported by growing clinical acceptance, broader insurance coverage, and demand for non-invasive cancer monitoring.
• The largest growth opportunity lies in companion diagnostic co-development partnerships and expansion into high-growth Asia Pacific markets, particularly China, Japan, and South Korea.

Key Growth Determinants

• FDA Companion Diagnostic Approvals Mandating PD-L1 Testing Across Expanding Tumour Types

Oncology diagnostic laboratories face an immediate commercial imperative: every new checkpoint inhibitor label that specifies a PD-L1 expression threshold creates a non-discretionary testing episode, directly expanding addressable test volume rather than competing with existing assays. The FDA approved Dako 22C3 pharmDx as a companion diagnostic for Merck's Keytruda in cervical cancer in 2018 and has since expanded companion diagnostic designations to include gastric, oesophageal, and triple-negative breast cancer indications through 2023, broadening the patient population that legally requires testing before treatment initiation.

 Over the next two to three years, pipeline approvals for PD-L1/PD-1 combination therapies targeting small cell lung cancer and hepatocellular carcinoma with at least six NDA submissions pending review as of 2024 will add further mandatory testing triggers, sustaining above-market revenue growth for diagnostic platform providers.

Key Growth Barriers

• Assay Heterogeneity and Lack of Cross-Platform Standardisation Suppressing Clinical Adoption

The absence of a universal PD-L1 scoring standard creates procurement friction: hospital pathology departments must maintain multiple validated assay platforms simultaneously because each approved checkpoint inhibitor references a distinct companion diagnostic clone, inflating capital expenditure and reagent costs by an estimated 20–35% compared to a unified-platform environment.

The Blueprint PD-L1 IHC Comparability Project, a multi-pharma initiative coordinated with input from the College of American Pathologists, demonstrated that antibody clones 28-8, 22C3, SP142, and SP263 produce concordant results only at high expression levels, leaving clinical laboratories unable to substitute assays across indications without re-validation, a process requiring 6–12 months of analytical performance data. Community hospitals and smaller reference laboratories which lack the capital and technical personnel for multi-platform validation are disproportionately disadvantaged, effectively ceding complex PD-L1 testing volumes to centralised academic reference labs and slowing market penetration at the community care level. 

PD-L1_Biomarker Testing Market Opportunity

• Liquid Biopsy Integration Unlocking Repeat Testing and Treatment Monitoring Revenue Streams

Diagnostic platform developers and oncology-focused venture capital investors should prioritise liquid biopsy-based PD-L1 assay development as a high-margin, recurring-revenue opportunity distinct from the one-time tissue biopsy model, since liquid biopsy enables longitudinal monitoring of immunotherapy response rather than a single pre-treatment decision. Guardant Health's Guardant360 platform, which received FDA Breakthrough Device Designation in 2023 for its comprehensive liquid biopsy panel, demonstrated the regulatory pathway viability for blood-based companion diagnostics and signalled that payers and regulators are prepared to reimburse non-invasive genomic profiling at commercially viable rates.

Diagnostic companies with existing liquid biopsy infrastructure particularly those holding CLIA-certified laboratory operations in the United States are best positioned to capture this opportunity, provided they secure prospective clinical validation data linking circulating tumour DNA-derived PD-L1 signals to immunotherapy response outcomes in pivotal-scale trials.

Market Segmentation Analysis

Test Type Analysis

Non-Small Cell Lung Cancer (NSCLC) accounts for 43.6% of the global PD-L1 biomarker testing market in 2026, equivalent to US$ 366.28 Million, driven by its status as the first solid tumour indication for which the FDA mandated companion diagnostic PD-L1 testing as a prerequisite for first-line Keytruda monotherapy eligibility.

Thoracic oncologists at NCI-designated cancer centres and community pulmonology practices routinely order Dako 22C3 pharmDx or Ventana SP263 assays on every newly diagnosed advanced-stage NSCLC biopsy specimen a standardised workflow embedded in NCCN Guidelines Version 3.2023 meaning that testing is triggered automatically at diagnosis rather than as a discretionary clinical decision.

Haematological Malignancies represent the fastest-growing test type segment, fuelled by the 2023 EMA approval of nivolumab (Bristol-Myers Squibb's Opdivo) in combination with chemotherapy for relapsed/refractory diffuse large B-cell lymphoma, which created the first formal haematology-specific clinical context requiring PD-L1 expression assessment in European oncology centres and is now prompting analogous regulatory submissions in the United States and Japan, rapidly expanding the addressable testing population.

Technology Analysis

Immunohistochemistry (IHC) Based Testing accounts for 71.8% of the global PD-L1 biomarker testing market in 2026, equivalent to US$ 603.19 Million, because hospital pathology laboratories already possess IHC staining infrastructure, validated interpretation protocols, and trained histopathologists making IHC the zero-incremental-capital-expenditure choice for every institution that needs to add PD-L1 testing capacity.

Agilent Technologies' Dako Autostainer Link 48 and Roche Diagnostics' BenchMark ULTRA platforms dominate clinical laboratory procurement across North American and European cancer centres, and their pre-analytical and staining parameters are already written into companion diagnostic product inserts approved by both the FDA and CE-IVD regulatory frameworks, creating a formidable switching-cost moat.

Next Generation Sequencing (NGS) Based Testing is the fastest-growing technology segment, accelerated by the FDA's 2023 approval of Illumina's TSO 500 as a companion diagnostic for multiple biomarkers simultaneously including PD-L1 expression, tumour mutational burden, and microsatellite instability enabling oncology centres to replace three separate assays with a single NGS run and deliver a comprehensive immunotherapy-eligibility report from a single formalin-fixed paraffin-embedded tissue section.

Sample Type Analysis

Tissue Biopsy Samples account for 82.6% of the global PD-L1 biomarker testing market in 2026, equivalent to US$ 693.92 Million, because all currently approved FDA companion diagnostic labels for checkpoint inhibitors specify formalin-fixed paraffin-embedded (FFPE) tumour tissue as the validated sample matrix making tissue biopsy the only sample type with a clear regulatory and reimbursement pathway across the full spectrum of approved indications.

Surgical pathology departments at comprehensive cancer centres routinely process FFPE blocks from bronchoscopic, core needle, or surgical resection specimens through validated IHC staining runs, with PD-L1 testing added reflexively to the diagnostic workup; Mayo Clinic Laboratories lists reflex PD-L1 IHC testing as a standard companion service for all newly diagnosed lung cancer specimens processed through its reference laboratory network. 

Blood-Based Liquid Biopsy is the fastest-growing sample type, catalysed by Foundation Medicine's FoundationOne Liquid CDx, which received FDA approval in 2020 and expanded its clinical utility claims through 2023–2024 to encompass additional solid tumour types, establishing a commercially reimbursed precedent that is now prompting hospital oncology teams to deploy serial blood draws for treatment monitoring a use case tissue biopsy cannot serve and drawing new payer coverage commitments from major U.S. insurers including UnitedHealth Group.

Regional Insights

North America PD-L1 Biomarker Testing Market Trends and Insights

North America accounts for 41.3% of the global PD-L1 biomarker testing market in 2026, representing US$ 346.96 Million, underpinned by the world's highest per-capita oncology drug expenditure and a regulatory infrastructure centred on the FDA's companion diagnostic co-approval framework that directly mandates testing at every point of immunotherapy initiation.

North America's dominance will persist through 2033 as pipeline checkpoint inhibitor approvals continue to generate new companion diagnostic co-submissions from established and emerging pharmaceutical developers.

United States PD-L1 Biomarker Testing Market Size

The United States PD-L1 biomarker testing market represents 87.4% of the North America regional market in 2026, equivalent to US$ 303.24 Million, driven primarily by the concentration of NCI-designated cancer centres 71 federally designated facilities as of 2024 each of which operates high-throughput diagnostic pathology laboratories with mandatory PD-L1 testing workflows embedded in institutional treatment protocols.

The Centers for Medicare and Medicaid Services (CMS) Local Coverage Determinations for companion diagnostic testing continue to expand covered indications, and further coverage expansions tied to new drug label approvals anticipated through 2027 will sustain test volume growth above the national healthcare spending baseline.

Asia Pacific PD-L1 Biomarker Testing Market Trends and Insights 

Asia Pacific accounts for 15.4% of the global PD-L1 biomarker testing market in 2026, representing US$ 129.38 Million, and registers the fastest regional CAGR of 15.4%, driven by the dual forces of rapidly expanding cancer incidence IARC GLOBOCAN 2022 estimated that Asia accounts for approximately 49% of global new cancer cases and accelerating regulatory harmonisation of companion diagnostic frameworks across China, Japan, and South Korea.

China's National Medical Products Administration (NMPA) approved sintilimab (a domestic PD-1 inhibitor developed by Innovent Biologics) with a companion PD-L1 testing requirement in 2021, setting a precedent that domestic and multinational diagnostic manufacturers are now leveraging to scale distribution across Chinese hospital networks.

China PD-L1 Biomarker Testing Market Size 

The China PD-L1 biomarker testing market represents 40.4% of the Asia Pacific regional market in 2026, equivalent to US$ 52.27 Million, propelled by the NMPA's accelerated approval pathway for oncology diagnostics introduced under the 2019 Drug Administration Law, which has reduced companion diagnostic review timelines from an average of 36 months to approximately 18 months and enabled faster commercial deployment of validated PD-L1 assay kits.

China's "Healthy China 2030" national initiative allocates increased provincial healthcare budgets toward cancer early detection and precision medicine infrastructure, signalling sustained government-backed demand for biomarker testing capacity through the forecast period.

Japan PD-L1 Biomarker Testing Market Size 

The Japan PD-L1 biomarker testing market represents 29.8% of the Asia Pacific regional market in 2026, equivalent to US$ 38.55 Million, anchored by the Pharmaceuticals and Medical Devices Agency (PMDA)'s rigorous companion diagnostic co-review framework, which mandates that drug developers submit diagnostic validation data simultaneously with therapeutic NDAs, ensuring high testing compliance rates across Japanese oncology centres.

Sysmex Corporation's expansion of its HISCL immunoassay platform toward oncology biomarker applications, announced in its FY2023 annual report, signals that domestic instrumentation developers are positioning to capture a greater share of Japan's hospital-based diagnostic spend as PD-L1 testing volumes scale.

South Korea PD-L1 Biomarker Testing Market Size 

The South Korea PD-L1 biomarker testing market represents 12.3% of the Asia Pacific regional market in 2026, equivalent to US$ 15.91 Million, supported by South Korea's Ministry of Food and Drug Safety (MFDS) having approved multiple domestic checkpoint inhibitors with mandatory PD-L1 testing prerequisites, embedding diagnostic testing into standard oncology pathways across the country's 42 regional cancer centres.

Samsung Biologics and Celltrion's expanding biosimilar and novel immunotherapy pipelines are expected to generate additional companion diagnostic co-development opportunities, positioning South Korean diagnostic laboratories for above-regional-average test volume growth through 2029.

Competitive Landscape

The PD-L1 biomarker testing market operates as a moderately consolidated oligopoly at the assay-platform level, with F. Hoffmann-La Roche Ltd. (through Ventana Medical Systems) and Agilent Technologies (through the Dako franchise) collectively controlling an estimated 55–60% of validated companion diagnostic assay revenue through their respective SP263 and 22C3 clone portfolios. Competition centres on companion diagnostic co-development agreements with pharmaceutical companies, speed of FDA companion diagnostic co-submission, and installed-base staining platform penetration in academic medical centres.

Thermo Fisher Scientific is the primary disruptive challenger, leveraging its Oncomine and Ion Torrent-anchored NGS portfolio to migrate PD-L1 scoring from standalone IHC assays into multi-biomarker panel workflows a strategy that threatens to commoditise single-analyte IHC revenue over the medium term. Winners are separating from laggards by securing prospective companion diagnostic label claims on pipeline drugs rather than competing for retrospective market share on already-generic indications.

Companies Covered in the PD-L1 Biomarker Testing Market 

• F. Hoffmann-La Roche Ltd.
• Agilent Technologies, Inc.
• Merck and Co., Inc.
• Bristol-Myers Squibb
• Thermo Fisher Scientific
• Abcam plc.
• Abbott Laboratories
• Illumina, Inc.
• Guardant Health, Inc.
• Foundation Medicine, Inc.
• Danaher Corporation (Leica Biosystems)
• Bio-Techne Corporation
• Cell Signaling Technology, Inc.
• Sysmex Corporation
• Innovent Biologics, Inc.

Market Segmentation

By Test Type

• Non-Small Cell Lung Cancer NSCLC
• Melanoma
• Renal Cell Carcinoma
• Gastrointestinal Tract Malignancy
• Haematological Malignancies
• Ovarian Cancer
• Other

By Technology

• Immunohistochemistry IHC Based Testing
• Polymerase Chain Reaction Based Testing
• Next Generation Sequencing Based Testing

By Sample Type

• Tissue Biopsy Samples
• Blood Based Liquid Biopsy

Regions

• North America
• Europe
• East Asia
• South Asia & Oceania
• Latin America
• Middle East & Africa